{"id":3636,"date":"2022-11-11T12:50:44","date_gmt":"2022-11-11T12:50:44","guid":{"rendered":"https:\/\/www.touchmedicalmedia.com\/?p=3636"},"modified":"2022-11-11T12:50:44","modified_gmt":"2022-11-11T12:50:44","slug":"world-diabetes-day-2022","status":"publish","type":"post","link":"https:\/\/www.touchmedicalmedia.com\/news\/world-diabetes-day-2022\/","title":{"rendered":"World Diabetes Day 2022"},"content":{"rendered":"

\"\"<\/p>\n

To fully appreciate why <\/span>World Diabetes Day<\/strong> is so important, it helps to lay out the severity of the mounting diabetes pandemic in its numbers \u2013 and they are pretty stark.<\/span><\/p>\n

Figures from 2021 show that around<\/span> 537 million adults between the ages of 20\u201379 years old live with diabetes worldwide \u2013 almost half of those are undiagnosed and 6.7 million could die as a result. (<\/span>IDF<\/span><\/a><\/span>)<\/span><\/p>\n

In 2020 world population numbers put the number of adults between 20\u201379 years old at approximately 5 billion<\/span>.<\/b> (<\/span>UN, World Population Prospects<\/span><\/span><\/a>)\u00a0<\/span><\/p>\n

In other words, roughly 10%+ of the global adult population have either type 1 (affecting <\/span>~10%<\/span><\/a><\/span>) or type 2 diabetes (affecting <\/span>~90%<\/span><\/span><\/a>). Those figures are not expected to fall over the next two decades, with diabetes projected to affect 643 million adults by 2030 and 783 million by 2045. (<\/span>IDF<\/span><\/span><\/a>) That is a 40% surge over the next 25 years.\u00a0<\/span><\/p>\n

Even more sobering is to remember that these numbers reflect only those with diabetes <\/span>right now<\/span><\/i>. When the risk factors associated with type 2 diabetes are considered, studies suggest that around 541 million adults are at increased risk of developing the disease. (<\/span>IDF<\/span><\/a><\/span>) (Type 1 diabetes cannot be prevented and the environmental triggers behind it are not yet fully understood).\u00a0<\/span><\/p>\n

READ:<\/strong> Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes<\/span><\/span><\/a><\/p>\n

Looking at some of the risk factors associated with type 2 diabetes, an alarming projection like this could be arguably symptomatic of modern society and in particular the changes to our physical activity levels and diet.\u00a0<\/span><\/p>\n

Risk factors include:<\/span><\/p>\n